| Administration route |
subcutaneous injection |
| Dosage |
300 mg |
| Pts |
85 |
| Age |
Adult, Older_Adult |
| Outcome |
47.1 percent of participants decreased of >=7% from Baseline in weight.11.8 percent of participants increased of >=7% from Baseline in weight. |
| Adverse reactions |
15/85(All-cause mortality); 46/85(Blood and lymphatic system disorders; Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders) |
|